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The current study evaluated antidiabetic and antihyperlipidemic activities of aqueous extract of 
Sigesbeckia orientalis L. (St. Paul’s Wort) (AESO) in an alloxan-induced diabetic rat model. Following 
OECD guidelines safe doses of AESO were assessed in rats for the main study. Serum/bood glucose, 
α-amylase, and lipids levels and histopathological evaluations were conducted to assess antidiabetic 
and associated antihyperlipidemic efficacies of AESO. AESO was found to be safe up to the dose of  
2000 mg/kg. Significant (p < 0.05) reduction in glucose and lipids (total cholesterol, triglycerides, 
low-density lipoproteins) levels was observed in AESO treatment groups. Serum α-amylase, high-density 
lipoproteins, and total body weight was increased significantly (p < 0.05) in diabetic rats treated 
with AESO. Histopathological data showed improvement in hepatocyte and pancreatic β-cells islets 
architecture. HPLC analysis identified quercetin, gallic acid, vanillic acid, p-coumaric acid, m-coumaric 
acid and cinnamic acid in AESO which are suggested to be responsible for observed antihyperglycemic 
and antihyperlipidemic attributes. Further studies to standardise the extract and evaluation of safety 
profile in long-term toxicity studies are recommended for safe and effective antidiabetic nutraceuticals 
development. 
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INTRODUCTION
Management and treatment of chronic disorders 
is one of the greatest challenges scientific communities 
facing in this modern era. In spite of major advancements 
in the healthcare system, scientists are still incapable of 
uprooting major chronic diseases like diabetes mellitus 
(DM). DM is a metabolic disorder during which human 
body loses its ability to regulate blood glucose levels 
which may be due to an abnormality in insulin production, 
resistance to peripheral effects of insulin or both and 
occurring simultaneously with abnormal carbohydrates, 
fats and proteins metabolism (Ramachandran et al., 2011). 
It may be asymptomatic or appear with most devastating 
symptoms like ketoacidosis or non-ketonic hyperosmolar 
state ultimately resulting in coma. Common symptoms 
of DM include extensive thirst, polyuria, weight loss, 
polyphagia, inability of body’s healing capacity and 
blurring of vision etc. (WHO, 2016). Physical inactivity 
and modern food intake habits have multiplied prevalence 
of DM over the years, which is 67% higher than estimates 
of 2004 (Shaw, Sicree, Zimmet, 2010). According to the 
World Health Organization (WHO) estimates, diabetic 
patients were estimated to be 108 million in 1980 and 
now this number has reached up to 422 million. Pakistan 
is among the top 10 countries (ranking 7th position) which 
are having high diabetic prevalence. Current prevalence 
of diabetes in Pakistan is documented to be 7.6-11% 
and is claimed to reach up to 15% by 2030 which will 
place Pakistan at 4th position in the world (Hussain, Ali, 
2016). Majority of diabetes medications have imperfect 
glycemic control and have side effects including weight 
gain, diarrhoea, nausea, and lactic acidosis, reflecting the 
limitations of current pharmacotherapy (Tsang, 2012). 
The WHO has emphasized on the use of ethanomedicines 
for diabetic control. According to the reports, more 
than 1200 plants have been traditionally used for their 
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hypoglycemic effects, out of which 800 plants have 
been scientifically reported to have antidiabetic potential 
(Pandey et al., 2011). Plants and plant-derived products 
have additional advantages of safety, low cost, and ease 
of availability along with their multi-targeting ability due 
to presence of diverse chemical compounds which may 
provide synergistic actions against diabetes. Multiple 
plant extracts/ derived products are available in Asian 
herbal markets as antidiabetic agents like; “Diabet 
GuardTM Granules” is an Indian antidiabetic herbal product 
containing Azadirachta indica, Eugenia jambolana, 
Gymnema sylvestre, Momordica charantia, and Tinospora 
cordifolia as active agents (Aggarwal, Shishu, 2011). 
Sigesbeckia orientalis L. (St. Paul’s Wort) is 
annually grown natural herb of family Asteraceae and 
has been used traditionally for the treatment of multiple 
ailments (Wang et al., 2011). It is found in tropical, 
subtropical, temperate zones as well as in Africa and 
Asia (Wang et al., 2011). It is also used topically for the 
treatment of syphilis, leprosy, gangrenous ulcers and sores 
(Khare, 2008). A number of pharmacologically active and 
useful phytochemical constituents are part of this herb and 
are suggested to be responsible for its health promoting 
activities. Bioactive chemical compounds found in aerial 
parts of S. orientalis include sesquiterpene lactone, 
orientin, and diterpenes. 3, 7-dimethyl quercetin has been 
reported to be found in abundance in whole plant (Khare, 
2008). It has been reported to have anti-inflammatory, 
analgesic, antirheumatic, antimalarial, antihypertensive, 
immunosuppressant, anti-snake venom, and anti-
proliferative (against human endometrial RL-95 cancer 
cells) activities (Sun, Wang, 2006; Wang et al., 2011; 
Chang et al., 2015). Traditionally the whole plant is used 
as a hypoglycemic agent (Marles, Farnsworth, 1995) but to 
best of our knowledge, there is no scientific study available 
that reports the antihyperglycemic and antihyperlipidemic 
activities of S. orientalis. Therefore, the current study 
was designed with an objective to evaluate antidiabetic 
potential of aqueous extract of S. orientalis whole plant 
in an alloxan-induced diabetic rat model.
MATERIAL AND METHODS
Plant material and extract preparation
Aqueous extract of S. orientalis (AESO) whole 
plant was prepared by maceration. After collection and 
washing with tap water, the whole plant was dried under 
shade. Subsequently, dried material was powdered, sieved, 
macerated in water with occasional shaking and then 
filtered through grade I Whatmann filter paper. Finally, 
filtrate was spray dried in vacuum drying apparatus. AESO 
was obtained in form of a fine (brown colour) powder 
which was kept in airtight container in fridge at 4 °C until 
further experimentation. AESO was dissolved in distilled 
water for all in vivo studies.
Plant material was collected by Dr. Saadullah 
from Swat Valley, Pakistan and identified by the expert 
taxonomist, Dr Altaf Ahmed Dasti, Institute of Pure and 
Applied Biology, BZU, Multan, Pakistan and specimen no 
Steward SO231 was allotted for future reference.
Animals
Albino rats of either sex weighing 150-200g 
were purchased from the animal house of University of 
Agriculture, Faisalabad, Pakistan and were kept at animal 
housing facility of Faculty of Pharmaceutical Sciences, 
Government College University Faisalabad (GCUF) 
with free access to routine feed and water ad libitum. The 
housing environment was set at standard environmental 
conditions i.e., temperature set at 22 ± 2 °C with 
alternative dark and light cycle of 12 hours. All the in vivo 
experiments were carried out with the prior  of Institutional 
Animal Ethical Committee of GCUF, Pakistan (Study No. 
19599 and Ref.No.GCUF/ERC/1999).
Acute toxicity studies
The acute oral toxicity study was conducted as per 
OECD guideline No. 423 for a period of 14 days. Albino 
rats of either sex were weighed and marked individually 
for proper observation purpose. They were then kept in 
Individual cages at room temperature, i.e., 22 ± 2 °C and 
30% humidity. Food but not water was withdrawn from 
all animals overnight prior to AESO administration and 
3-4 hours post administration. AESO was administered via 
oral route at doses of 5, 50, 300 and 2000 mg/kg in 2 mL of 
distilled water. 3 animals were used for each dosing level as 
recommended by guideline. Changes in skin, eyes, fur and 
mucous membrane colour were noted along with any sign 
of tremors, convulsions, salivation, diarrhoea, lethargy and 
sleep etc. Changes in body weight were recorded before, 
during and at the end of study (OECD, 2002).
Induction of diabetes
Diabetes was induced in overnight fasted rats by 
intraperitoneal injection (IP) of alloxan monohydrate 
(150 mg/kg body weight), freshly prepared in normal 
saline. 20% dextrose solution (w/v) was administered 
after 6 h to prevent alloxan-induced hypoglycemia due 
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to the massive release of insulin from pancreas. For the 
next 24 h, rats were maintained on 5% glucose in drinking 
water. After 72 h, blood glucose was checked by using 
Accu-Answer® digital glucose sensor. Animals with blood 
glucose greater than 200 mg/dL were selected and allowed 
to stabilize for 1 week before detailed experimentations 
(Sornalakshmi et al., 2016).
Oral glucose tolerance test
Oral glucose tolerance test (OGTT) for AESO 
was conducted in normal and hyperglycemic rats. 
Animals were divided into nine groups of 6 animals 
each (n = 6). Four groups were used for OGTT in normal 
rats and five groups were used for OGTT in diabetic 
rats. Glibenclamide (10 mg/kg) was used as standard 
antidiabetic drug (Table I). Animals were given glucose 
at concentration of 2 g/kg body weight after 1 h of AESO 
administration in experimental groups and blood glucose 
levels were measured by one touch Accu-Answer® digital 
glucometer at different time interval i.e., 0, 0.5, 1, 2, 3 and 
6 h respectively (Sornalakshmi et al., 2016).
 
Determination of glucose and other biochemical 
parameters
In order to check antidiabetic potential of AESO, 
blood glucose levels were monitored by one touch Accu-
Answer® digital glucometer on day 0, 3, 6, 9, 12 and 
14 respectively. Blood samples for other biochemical 
parameters were collected at the end of the study by 
sacrificing animals. Gel vacutainers were used to collect 
blood samples. Collected blood was allowed to coagulate 
in the refrigerator for 20 minutes, then centrifuged for 
3-5 minutes and serum was collected and analysed for 
total cholesterol (TC), triglycerides (TG), high-density 
lipoproteins (HDL), low-density lipoproteins (LDL) 
and serum amylase levels respectively. TC, HDL, TG 
levels were determined using Crescent diagnostic assay 
kits following manufacturer recommended methods 
(CHOD-PAP, phosphotungstic-precipitation and 
GPO-PAP method respectively). Calorimetric estimation 
of serum amylases was carried using assay kit of amylase 
activity. LDL levels were calculated using Friedwald 
equation given below (Chaudhry et al., 2016).
LDL (mg/dL) = TC - HDL - TG/5
Body weight changes
Animals were observed for changes in their body 
weight before starting treatment (day 0) and during (day 7) 
and at the end of study (day 14) respectively.
Histopathological examination
Liver and pancreas of animals were excised for 
histopathological investigations using Haematoxylin and 
Eosin (H&E) stains. Changes in morphology of pancreatic 
cells and hepatocytes were observed under the microscope 
using 20× and 40× magnifications (Suvarna, Layton, 
Bancroft, 2012). 
Preliminary phytochemical evaluation through 
HPLC
Shim-pack CLC-ODS (C-18) reversed phase column 
(25 x 4.6 mm) packed with 5 µm diameter particles was 
used to carry out HPLC analysis. Doubled distilled water 
with acetic acid (94:6) at pH 2.27 and acetonitrile were 
TABLE I -OGTT treatment groups
Sr. No Group Treatment
Normoglycemic rats
1 Group I (Control) Received routine feed and normal saline
2 Group II (Glibenclamide 10 mg/kg) Received routine feed + glibenclamide (10 mg/kg)
3 Group III (AESO 250 mg/kg) Received routine feed + AESO at dose 250 mg/kg body weight
4 Group IV (AESO 500 mg/kg) Received routine feed + AESO at dose 500 mg/kg body weight
Hyperglycemic rats
5 Group I (Control) Normal rats received routine feed + normal saline
6 Group II (Diabetic control) Diabetic rats received routine feed + normal saline
7 Group III (Glibenclamide 10 mg/kg) Received routine feed + glibenclamide (10 mg/kg)
8 Group IV (AESO 250 mg/kg) Received routine feed + AESO at dose 250 mg/kg body weight
9 Group V (AESO 500 mg/kg) Received routine feed + AESO at dose 500 mg/kg body weight
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used as mobile phase I and II respectively. Acetonitrile was 
run as 15% from 0-15 minutes, 45% from 15-30 minutes 
and 100% from 30-45 minutes. Flow rate of mobile phase 
was 1 mL/ minute. Recordings were obtained at 280 nm 
wavelength using UV-visible detector. Chromatogram was 
plotted between units of voltage and time in minutes along 
x- and y-axis respectively. Compounds were identified 
by comparing the peaks of separated compounds and 
reference compounds (Ramachandran et al., 2011).
Compounds were identified by comparing the peak 
retention times with reference standards. Please see the 
supplementary file for standards HPLC chromatograms 
(Figure S1).
Statistical analysis
Data presented as mean ± S.E.M of three independent 
experiments (n = 3). One way analysis of variance 
(ANOVA), followed by Tukey’s Post Hoc test was 
performed to estimate difference between different groups. 
A statistical significance criterion was p < 0.05.
RESULTS
HPLC characterization of AESO
HPLC analysis of AESO led to the identification 
of compounds from flavonoids and phenols family i.e., 
quercetin, vanillic acid, coumaric acid, and cinnamic acid 
respectively (Figure 1).
Acute toxicity assessment of AESO
Data of oral acute toxicity test (supplementary Table 
S1) showed neither any sign of morbidity nor mortality in 
animals given single dose of 2000 mg/kg of AESO. 
Hypoglycemic effects of AESO in oral glucose 
tolerance test (OGTT)
Significant decrease (p < 0.05) in blood glucose 
levels was observed in normoglycemic rats at 6th h 
of glucose administration in AESO-treated animals 
compared with the control group. While, in hyperglycemic 
rats, treatment with 500 mg/kg of AESO significantly 
(p < 0.05) lowered blood glucose levels after 3 h of 
glucose administration. Treatment with 250 mg/kg of 
AESO showed its significant effects at 6th h of glucose 
administration when compared with glucose levels in the 
control group (Table S2).
Hypoglycemic effects of AESO in Alloxan-induced 
diabetic rats
Significant reduction in blood glucose levels was 
observed in blood samples of animals treated with AESO 
for 14 days (Table II). No significant changes in levels of 
glucose were observed in blood samples of animals treated 
with AESO (250 and 500 mg/kg) and glibenclamide 
(10 mg/kg) after 24 h of treatment. After 72 h of treatment 
significant decrease (p < 0.05) in blood glucose levels was 
observed in glibenclamide treatment group, while in AESO 
did not induce significant hypoglycemic effects when 
compared with glucose levels of diabetic control group. 
From day 6 to 14 significant (p < 0.05) decrease in levels of 
glucose was observed in blood samples of animals treated 
with AESO (250 and 500 mg/kg) and glibenclamide 
(10 mg/kg) respectively when compared with glucose 
levels in blood samples of diabetic animals (Figure 2)
Antihyperlipidemic effects of AESO in Alloxan-
induced diabetic rats 
Total cholesterol
Significant increase (p < 0.05) in serum total 
cholesterol levels was observed in diabetic animals 
(129.33 ± 4.10 mg/dL) as compared to the control group 
(73.50 ± 1.23 mg/dL) (Table III). Significant reduction 
(p < 0.05) in serum total cholesterol level was observed 
in animals treated with 250 and 500 mg/kg of AESO 
(113.67 ± 4.12 and 75.67 ± 6.06 mg/dL) and 10 mg/kg of 
glibenclamide (63.17 ± 7.32 mg/dL), when compared with 
the diabetic control group (129.33 ± 4.10 mg/dL) (Figure 3).
Triglycerides (TG)
Table III shows changes in serum triglycerides levels 
in different treatment groups. Significant increase (p < 0.05) 
FIGURE 1 - HPLC chromatogram of aqueous extract of 
Sigesbeckia orientalis. Where peak 7 = quercetin, peak 9 = gallic 
acid, peak 12 = vanillic acid, peak 13 = p-coumeric acid, peak 
14 = m-coumeric acid and peak 16 = cinamic acid.
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in serum triglycerides was observed in alloxan-induced 
diabetic rats (118.33 ± 7.00 mg/dL) when compared with the 
control group (72.83 ± 1.70 mg/dL). When compared with 
diabetic control group (118.33 ± 7.00 mg/dL), significant 
reduction (p < 0.05) in triglyceride levels was observed 
in serum samples of animal treated with 250 and 500 
mg/kg of AESO (98.67 ± 2.76 and 55.00 ± 5.22 mg/dL) 
and 10 mg/kg of glibenclamide (73.67 ± 14.70 mg/dL) 
respectively.
High-density lipoproteins (HDL)
Significant reduction in serum HDL levels 
was observed in  al loxan-induced diabet ic  rats 
(6.50 ± 1.18 mg/dL) when compared with the control 
group (17.17 ± 0.60 mg/dL). Significant increase 
(p < 0.05) in levels of HDL was observed in serum samples 
of animals treated with 250 and 500 mg/kg of AESO 
(11.67 ± 1.12 and16.00 ± 0.93 mg/dL) and 10 mg/kg of 
glibenclamide (14.00 ± 0.77 mg/dL) and normal group 
(17.17 ± 0.60 mg/dL) when compared with HDL serum 
levels in diabetic rats (Table III and Figure 3).
Low-density lipoproteins (LDL)
Significant increase (p < 0.05) in serum levels 
of LDL was observed in alloxan-induced diabetic rats 
(74.17 ± 2.15 mg/dL) when compared with normal 
control group (40.67 ± 2.06 mg/dL). Whereas, significant 
reduction (p < 0.05) in LDL levels in serum samples 
of rats treated with 250 and 500 mg/kg of AESO 
(49.50 ± 0.96 and 38.50 ± 2.11 mg/dL) and 10 mg/kg of 
glibenclamide (44.17 ± 1.11 mg/dL) was observed when 
compared with serum LDL levels of rats in diabetic group 
(74.17 ± 2.15 mg/dL) (Table III and Figure 3).









0 72.0±1.67ns 69.83±02.57ns 79.33±06.02ns 70.67±02.08ns 71.83±04.19ns
1 72.5±1.57*** 473.67±56.58ns 368.50±56.15ns 433.33±39.62ns 414.33±43.47ns
3 72.0±2.84*** 472.00±58.17 327.67±67.96* 384.67±46.93 375.17±41.08
6 73.1 ± 2.51*** 474.00±56.26 284.00±69.67* 308.83±29.76* 292.67±37.49**
9 79.83±6.27*** 471.50±53.62 204.33±56.13*** 258.33±21.15** 209.00±18.94***
12 72.17±1.82*** 474.50±53.68 162.83±42.08*** 224.17±18.38*** 129.83±12.99***
14 71.67±2.68*** 474.67±54.79 115.17±25.68*** 158.50±19.04*** 90.67±05.31***
Values are expressed as mean ± SEM. Comparison was made between glucose levels in blood samples of alloxan-induced diabetic 
rats and AESO and glibenclamide treated animals. At day 0 and 1 no significant change in blood glucose levels was observed in 
any treatment group. Blood glucose levels in normal healthy rats remained significantly lower throughout the study. Where ns = 
non-significant, * = p < 0.25, ** = p < 0.01, *** = p < 0.001 and Diabetic control = Alloxan-induced diabetic rats (150 mg/kg) 
respectively.
FIGURE 2 - Effect of aqueous extract of Sigesbeckia orientalis 
on blood glucose levels in control and experimental groups at 
different days of treatment. Comparison was made between 
glucose levels in blood samples of alloxan-induced diabetic rats 
and AESO and glibenclamide treated animals. At day 0 and 1 
no significant change in blood glucose levels was observed in 
any treatment group. Blood glucose levels in normal healthy 
rats remained significantly lower throughout the study. Where 
ns = non-significant, * = p < 0.25, ** = p < 0.01, *** = p < 0.001 
and Diabetic control = Alloxan-induced diabetic rats 
(150 mg/kg) respectively.
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Serum α-amylase
Serum levels of α-amylase in control, diabetic, 
glibenclamide , AESO 250 and 500 mg/ kg treated groups 
were 516.83 ± 66.30, 220.67 ± 51.90, 536.17 ± 101.16, 
398.00 ± 54.18 and 553.83 ± 45.06 units/L respectively. 
Alloxan-indiced diabetic rats showed significant reduction 
(p < 0.05) in serum amylase levels. Whereas, increase 
in serum amylase level was observed in animals treated 
with 500 mg/kg of AESO and was comparable to both 
positive (glibenclamide treated) and control (vehicle 
treated) groups.
Changes in body weights
Diabetic rats showed a 16% decrease in body weight 
as compared with initial weight, whereas, increase in body 
weight was observed in diabetic animals treated with 10 
mg/kg of glibenclamide (14%) and 250 mg/kg (7%) and 




Figure 4 shows effects of different treatments on the 
morphology of liver cells. Mild sinusoidal dilation with 
minor necrosis was observed in tissue slides of animals 
treated with 250 mg/kg of AESO (Figure 4D). Treatment 
with 500 mg/kg of AESO showed normal hepatocytes with 
lobular regeneration (Figure 4E). 
Histopathology of pancreas
Histopathological evaluation of pancreas of normal 
rats showed normal islets cell morphology and architecture 
(Figure 5). Pancreas of rats in the diabetic group showed 
necrotic islets cells with dilated acini and shrinkage. 
Morphology of pancreas in glibenclamide-treated rats 
showed increase in islets size and proliferating beta 
cells and normal pancreatic architecture. Morphology 
of pancreas in rats treated with 250 mg/kg of AESO 
showed improved islets structure with minimal necrosis 
and relatively proliferating cells while at 500 mg/kg large 
patches of highly proliferating beta cells with normal 
pancreatic architecture was observed (Figure 5).
DISCUSSION
Diabetes mellitus (DM) is an endocrine disorder 
TABLE III - Effect of aqueous extract of Sigesbeckia orientalis on total cholesterol, triglycerides, low density lipoproteins and high 
density lipoprotein levels in different treatment groups
Treatments Parameters (mg/dL)
TC TG LDL HDL
Control 73.50±1.23*** 72.83±1.70*** 40.67±2.06*** 17.17±0.60***
Diabetic control 129.33±4.1 118.33±7.00 74.17±2.15 6.50±1.18
Glibenclamide (10 mg/kg) 63.17±7.32*** 73.67±14.70*** 44.17±1.11*** 14.00±0.77***
AESO (250 mg/kg) 113.67±4.12* 98.67±2.76** 49.50±0.96*** 11.67±1.12***
AESO (500 mg/kg) 75.67±6.06*** 55.00±5.22*** 38.50±2.11*** 16.00±0.93***
Values are expressed as mean ± SEM. Comparison was made between lipids levels in serum samples of alloxan-induced diabetic rats 
and AESO and glibenclamide treated animals Where TC = Total cholesterol, TG = Triglycerides, LDL = Low density lipoproteins, 
HDL = High density lipoproteins and Diabetic control = Alloxan-induced diabetic rats (150 mg/kg).
FIGURE 3 - Effect of aqueous extract of Sigesbeckia orientalis 
on total cholesterol, triglycerides, low density lipoproteins and 
high density lipoprotein levels in different treatment groups. 
Comparison was made between lipids levels in serum samples 
of alloxan-induced diabetic rats and AESO and glibenclamide 
treated animals Where ns = non-significant, * = p < 0.25, ** 
= p < 0.01, *** = p < 0.001, TC = Total cholesterol, TG = 
Triglycerides, LDL = Low density lipoproteins, HDL = High 
density lipoproteins and Diabetic control = Alloxan-induced 
diabetic rats (150 mg/kg).
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responsible for approximately 3 million deaths worldwide. 
It is caused due to an abnormality in metabolic processes 
either due to reduced insulin production, suppressed 
insulin actions or both happening at the same time (WHO, 
2016). Persistent hyperglycemia in DM leads to multiple 
microvascular and macrovascular complications affecting 
several organs, including muscle, skin, heart, brain, and 
kidneys (Fowler, 2011). According to some estimates, by 
year 2030, DM will be the 7th leading cause of mortality 
globally. It has victimized about 422 million people in 
2014 (Shaw, Sicree, Zimmet, 2010). Before 70 years of 
age, 50% of deaths are due to persistent hyperglycemia and 
its related complications. Majority of diabetic cases i.e., 
92% are recorded in lower economy countries. According 
to WHO, Pakistan is standing at 7th position in the list 
of high diabetic prevalence countries indicating need of 
urgent steps to address this chronic issue (WHO, 2016).
Treatment of diabetes with conventional drugs 
is very expensive and chances of side effects are high. 
Phytochemicals obtained from medicinal plants offer 
a promising alternative for the development of new 
therapeutic agents against DM. Most health-promoting 
phytochemicals obtained from natural products include 
flavonoids, terpenoids, cardiac glycosides, alkaloids, 
and steroids respectively (Ajiboye, Asekun, Familoni, 
2016). Out of these secondary metabolites polyphenols, 
in particular, flavonoids are suggested as better therapeutic 
agents in the management of DM and its chronic 
complications (Marella, 2017).
The current study was designed to explore the 
antidiabetic and antihyperlipidemic activities of aqueous 
extract of Sigesbeckia orieltalis L. in an alloxan-induced 
diabetic rat model. Before commencement of the main 
FIGURE 4 - Photomicrographs of effect of different treatments 
on liver architecture. A= liver of rats in control group showing 
normal hepatocytes architecture. B = photomicrograph of 
rat liver of diabetic group showing cell necrosis along with 
lymphocytes infiltration and sinusoidal dilation with the help 
of arrows. C = photomicrograph of rat liver in glibenclamide 
group showing almost same morphology as normal group 
with normal hepatocytes architecture. D = photomicrograph 
of rat liver in AESO 250 group showing improved hepatocyte 
architecture with mild sinusoidal dilation and minimal necrosis. 
Black arrows are showing sinusoidal dilations while white 
bold arrows are depicting improved hepatocyte architecture. 
E = photomicrograph of rat liver in AESO 500 group showing 
normal hepatocytes same as normal control with lobular 
regeneration (H & E stain, X20 & 40).
FIGURE 5 - Pancreas of control group showing normal islet 
cell morphology and architecture. B = pancreas of diabetic 
control group showing necrotic islet cells in circle with dilated 
acini and islet shrinkage. C = pancreas of glibenclamide-treated 
group showing increased islet size and proliferating beta cells 
(black arrows) and normal pancreatic architecture (bold arrows). 
D = pancreas of AESO 250 mg/kg treatment group showing 
improved islet structure with minimal necrosis and relatively 
proliferating cells. E = pancreas of AESO 500 mg/kg treatment 
group showing large patches of highly proliferating beta cells 
with normal pancreatic architecture. Bold arrows show normal 
cell architecture while black arrows show highly proliferating 
islet (H & E stain, X20 & 40).
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study, a preliminary toxicological study was conducted in 
order to select the safe doses for antidiabetic evaluations. 
The first priority in herbal research is an assessment of 
safety profile of herbal product and setting up a criterion 
for selecting a safe dose for human use (Yehya et al., 2018). 
Safety data obtained, showed that AESO was non-toxic up 
to the dose of 2000 mg/kg in normal healthy rats. Therefore, 
1/4th of this dose i.e., 500 mg/kg and below were selected 
for further detailed studies. Oral glucose tolerance test is 
conducted to determine ability of body to utilize glucose 
as well as apparent insulin release and insulin resistance in 
various clinical situations (Sornalakshmi et al., 2016). In 
the present study, significant decrease (p < 0.05) in blood 
glucose levels was observed in alloxan-induced diabetic 
rats treated with AESO. More prominent antihyperglycemic 
effects were observed in animals treated with 500 mg/
kg of AESO. This data demonstrates that AESO possibly 
improved insulin release from beta cells and prevented 
impaired glucose tolerance, which are two most important 
characteristics of DM (Chaudhry et al., 2016).
Alloxan is known to induce a hyperglycemia 
by destroying β-cells of pancreas via redox-mediated 
mechanisms. Auto-oxidation of glucose in hyperglycemic 
state can lead to lipid peroxidation, altered antioxidant 
defense mechanisms leading to further dysfunctions 
in glucose metabolism and are known to be mediated 
by reactive oxygen species (ROS) (Chaudhry et al., 
2016). In vitro antioxidant and anti-glycation activities 
of Siegesbeckia orientalis has recently been reported 
(Hung et al., 2017). Moreover, flavonoids have been shown 
to produce their antidiabetic effects through enhancement 
of insulin secretion via regeneration of pancreatic β-cells, 
enhancement of insulin mediated glucose uptake by target 
cells, inhibition of aldose reductase and increased uptake of 
Ca2+ respectively (Marella, 2017). HPLC analysis of AESO 
indicated the presence of compounds from flavonoids and 
phenols family i.e., quercetin, vanillic acid, coumaric acid 
and cinnamic acid respectively (Figure 1). Majority of these 
phytochemicals have been indicated to have antidiabetic 
attributes via different mechanisms (Adefegha et al., 2015; 
Amalan et al., 2016; Choi et al., 2010; Chang et al., 2015; 
Fachriyah, et al., 2017; Hafizur et al., 2015). Thus on the 
basis of these findings, it is proposed that multi-components 
of AESO having antioxidant and insulin-secreting and 
β-cells protective attributes are proposed to be responsible 
for observed hypoglycemic effects. 
Hyperglycemia and hyperlipidemia are two 
important characteristics of diabetes mellitus. Persistent 
hyperglycemia is known to be associated with altered 
lipid profile and changes in serum enzymes and total 
body weight etc. (Kumar, Kumar, Prakash, 2011). AESO 
treatment improved lipid profile by lowering serum 
TC, TG, and LDL and increasing serum HDL levels 
respectively. This observation suggests that changes 
in cholesterol absorption/ biosynthesis or changes in 
lipoprotein metabolism are suggested to be responsible 
for antihyperlipidemic effects of AESO in alloxan-induced 
diabetic rats. Taken together, these two observations i.e., 
antidiabetic and lipid-lowering activities suggest that 
AESO use may be able to prevent multiple diabetes-
associated cardiovascular diseases. Data of the current 
study is supported by another research report where 
similar types of changes in blood glucose and lipid profile 
were observed in alloxan-induced diabetic rats after 
administration of plant extract (Chaudhry et al., 2016). 
Histopathological evaluations showed alloxan 
induced degenerative changes in liver and pancreas of 
animals, which were in accordance with previous studies 
(Shah, Khan, 2014). Pancreas and liver of rats treated with 
AESO showed reversal of damages caused by alloxan-
induced hyperglycemia and resulted in normal liver and 
pancreatic architecture. 
Decrease in body weight due to muscle wasting is one 
of the characteristics of alloxan-induced diabetes. Moreover, 
change in body weight is used as an indicator of toxicity, as 
10% or more decrease in body weight when compared with 
initial weight highlights the toxic nature of plant extract/ 
isolated compound or synthetic drugs (Chaudhry et al., 
2016; Yehya et al., 2018). In the current study, increase in 
body weight in AESO-treated diabetic rats was observed, 
suggesting relatively safe nature of water extract. 
CONCLUSION
The current study highlights for the first time 
antidiabetic and antihyperlipidemic potential of aqueous 
extract of Sigesbeckia orientalis against alloxan-induced 
diabetes. Multicomponent synergism is suggested to 
be responsible for the observed effects. Further studies 
to standardise extract and to establish the safety profile 
of extract in chronic models before commencement of 
clinical trials are warranted. 
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